Enzolve Technologies, a UCD spin-out company, has formally launched its first CE-marked diagnostic test, which screens for phenylketonuria (PKU) in newborn babies. Enzolve's PKU test, based on engineered enzyme technology, has several advantages over the tests currently available on the market...
Read full article on the web Irish Medical News May 15, 2009 or in pdf format
Products & Services
Website supported by